Butadion pills 150 mg 10 pcs.

Composition

1 tablet contains:Active ingredient: phenylbutazone-150 mg

. Pharmacological action

of NSAIDs from the group of pyrazolone derivatives. Butadione has anti-inflammatory, analgesic and antipyretic effects due to inhibition of COX activity and a decrease in prostaglandin synthesis.

Indications

Inflammatory and degenerative diseases of the musculoskeletal system: rheumatoid, gouty, psoriatic arthritis, ankylosing spondylitis (Ankylosing spondylitis), osteoarthritis, arthritis in SLE (as part of complex therapy). Pain syndrome: bursitis, tendovaginitis, arthralgia, myalgia, neuralgia, tooth and headache (including migraine) pain, algodismenorrhea, pain from injuries, burns. Febrile syndrome in “colds” and infectious diseases. It is intended for symptomatic therapy, reducing pain and inflammation at the time of use, and does not affect the progression of the disease.

Contraindications

Hypersensitivity; complete or incomplete combination of bronchial asthma, recurrent nasal and paranasal sinus polyposis and intolerance to ASA or other NSAIDs (including in the anamnesis); erosive and ulcerative lesions of the gastrointestinal tract in the acute stage (peptic ulcer of the stomach and duodenum, ulcerative colitis, peptic ulcer), bone marrow depression, decompensated CHF or pulmonary heart failure, severe hepatic and/or renal insufficiency (creatinine clearance less than 30 ml/min), the period after coronary artery bypass grafting; progressive kidney disease, active liver disease, confirmed hyperkalemia, pregnancy (third trimester), active gastrointestinal bleeding, inflammatory bowel diseases. With caution. Hyperbilirubinemia, bronchial asthma, CHF, edema, arterial hypertension, hemophilia, hypocoagulation, liver failure, CRF, hearing loss, vestibular apparatus pathology, blood diseases, diabetes mellitus, SLE, polymyalgia rheumatoid, transient arteritis, ulcerative diseases of the gastrointestinal tract, stomatitis, coronary heart disease, cerebrovascular diseases, dyslipidemia/hyperlipidemia, heart diseases peripheral artery disease, smoking, CRF (creatinine clearance 30-60 ml/min), a history of gastrointestinal ulcers, H. pylori infection, old age, long-term use of NSAIDs, alcoholism, severe somatic diseases, concomitant use of oral corticosteroids (including prednisone), anticoagulants (including warfarin), antiplatelet agents (including acetylsalicylic acid, clopidogrel), selective inhibitors reuptake of serotonin (including citalopram, fluoxetine, paroxetine, sertraline), pregnancy, lactation.

Side effects

From the digestive system: dyspepsia, NSAIDs-gastropathy, abdominal pain, nausea, vomiting, heartburn, diarrhea or constipation; with prolonged use in large doses – ulceration of the gastrointestinal mucosa, aphthous stomatitis, glossitis, erosive esophagitis, bleeding (gastrointestinal, gingival, hemorrhoidal), liver dysfunction. From the cardiovascular system: increased blood pressure, tachycardia. Nervous system disorders: headache, dizziness, drowsiness, depression, agitation. Sensory disorders: hearing loss, tinnitus. Hematopoietic disorders: agranulocytosis, leukopenia, anemia, thrombocytopenia. Allergic reactions: skin rash, pruritus, urticaria, bronchospasm, edematous syndrome, angioedema. Other: increased sweating, uterine bleeding.

Interaction

Increases the effect of indirect anticoagulants, antiplatelet agents, fibrinolytics, side effects of corticosteroids and MCS, estrogens, morphine, PASC, penicillin, hypoglycemic effect of sulfonylurea derivatives. Reduces the effectiveness of uricosuric, antihypertensive drugs and diuretics. Increases the concentration of Li+ and methotrexate in the blood. Inducers of microsomal oxidation in the liver (phenytoin, ethanol, barbiturates, rifampicin, tricyclic antidepressants) increase the production of hydroxylated active metabolites. Antacids and colestyramine reduce absorption. Myelotoxic drugs increase the manifestations of hematotoxicity of the drug.

How to take, course of administration and dosage

Inside,0.2-0.4 g during or after meals 3-4 times a day. Children aged from 6 months – 0.01-0.1 g (depending on age) 3-4 times a day. The duration of therapy is 2-5 weeks or more.

Overdose

Symptoms: cyanosis of the fingertips, lips, body skin, dizziness, headache, increased or decreased blood pressure, hyperventilation of the lungs, blurred consciousness, in children-myoclonic convulsions, nausea, vomiting, abdominal pain, hemorrhages, impaired liver and kidney function. Treatment: gastric lavage, administration of activated charcoal, symptomatic therapy aimed at maintaining vital body functions. Forced diuresis and hemodialysis are ineffective.

Special instructions

During treatment, it is necessary to monitor the picture of peripheral blood and the functional state of the liver and kidneys. If it is necessary to determine 17-ketosteroids, the drug should be discontinued 48 hours before the study. During treatment, you should refrain from engaging in potentially dangerous activities that require increased attention and speed of mental and motor reactions. To reduce the risk of gastrointestinal adverse events, the minimum effective dose should be used in the shortest possible course.

Active ingredient

Phenylbutazone

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

Pregnant women only in the second trimester as prescribed by a doctor, Children over 15 years of age, For adults, For adults as prescribed by a doctor

Indications

Sciatica, Bruises, Rheumatoid Arthritis, Arthrosis and Arthritis, Dislocations and Sprains, Osteoarthritis, Trigeminal Neuralgia, Lumbago

Weight

Weight: 20 g.